
Woman loves how her 'Ozempic face' looks
One Ozempic user loves how her face looks after losing weight.
Although it's become so normalized for people to lose weight using GLP-1 — many are suffering from its bizarre side effects, like 'Ozempic face,' except for a woman named Alejandra Salomon.
Salomon noticed a big difference in how her face looked after she took Semaglutide, a compound version of Ozempic, to lose weight for her sister's wedding. 60 pounds lighter.
3 Many Ozempic users complain about their faces looking 'hollowed out' or sagging — but Salomon experienced the opposite.
Jam Press/@actuallyal__
While experts will say that Ozempic and similar weight loss drugs '… make the face look much older,' Dr. Patrick Byrne, president of the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS), told The Post.
Salomon — who is in her late twenties — feels the opposite. 'My weight loss made me look 10 years younger – no Botox needed,' she told NeedToKnow.
While some Ozempic faces are appearing older with sunken cheeks, gaunt eyes and sagging neck skin — that doesn't seem to be the case for Saloman as she's thrilled with how young her face looks.
'It looks like I got jawline filler but really, I lost 60lbs and got in the best shape of my life,' she told NeedToKnow.
The 20-something-year-old started taking the weight loss drug '…because my parents thought it would be a good idea to lose 20lbs for my sister's wedding.'
3 'It looks like I got jawline filler but really, I lost 60lbs and got in the best shape of my life,' she told NeedToKnow.
Jam Press/@actuallyal__
'It has without a doubt been the best decision for both my health and confidence,' she said.
Salomon doesn't view her slimmed-down face as a bad thing — if anything, she looks at it as a healthy change because she now thinks her once round face was a sign of inflammation.
She made sure to mention that although Semaglutide changed her life — it did come with some work.
'It is not an easy solution and is not a magic trick. I started to eat so much protein and switch up my workouts,' she admitted.
Salomon said she is no longer on the medication but is still working hard to keep herself healthy.
3 The 20-something-year-old is thrilled with how she looks.
Jam Press/@actuallyal__
'…I am no longer on medication, and am maintaining my weight!'
Aside from the Ozempic face change, another alarming side effect from the weight loss drug is 'Ozempic teeth.'
Those who use the GLP 1 might have experienced dental issues — such as dry mouth, bad breath and gum disease.
'Ozempic might reduce saliva production, diminishing the mouth's natural ability to cleanse teeth' — which can cause serious damage to one's teeth,' Dr. Michele Green told the Daily Mail.
'Saliva is crucial for protecting teeth, as it helps remove food particles, neutralizes acids produced by bacteria in the mouth and provides essential minerals that strengthen tooth enamel,' the expert said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Insider
2 hours ago
- Business Insider
Regeneron price target lowered to $650 from $700 at Citi
Citi analyst Geoff Meacham lowered the firm's price target on Regeneron (REGN) to $650 from $700 and keeps a Buy rating on the shares. The company reported mixed itepekimab Phase 3 COPD results in former smokers, the analyst tells investors in a research note. The firm says that wWhile Aerify-1 met its primary endpoint in both dosing arms, Aerify-2 failed to achieve statistical significance improvement at week 52. While Aerify-1 was positive, the path to approval is unclear, contends Citi. Confident Investing Starts Here:


Business Insider
5 hours ago
- Business Insider
Regeneron announces analyses from Phase 3 C-Post trial
Regeneron (REGN) Pharmaceuticals announced detailed analyses from the Phase 3 C-POST trial, which evaluated PD-1 inhibitor Libtayo in patients with high-risk cutaneous squamous cell carcinoma, CSCC, after surgery. The results, shared during an oral session at the 2025 American Society of Clinical Oncology, ASCO, Annual Meeting and simultaneously published in the New England Journal of Medicine, NEJM, include additional data for the primary endpoint of disease-free survival, DFS, and the first presentation of key secondary endpoint outcomes. With a median duration of follow-up of 24 months, efficacy results for Libtayo compared to placebo, were as follows: 68% reduction in the risk of disease recurrence or death, with median DFS not reached for Libtayo-treated patients; At two years, DFS was 87% with Libtayo versus 64% with placebo; 80% reduction in the risk of locoregional recurrence; 65% reduction in the risk of distant recurrence


Business Insider
5 hours ago
- Business Insider
Arcus Biosciences presented data for casdatifan plus cabozantinib
Arcus Biosciences (RCUS) presented the first data for casdatifan plus cabozantinib in an oral presentation by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute, at the 2025 American Society of Clinical Oncology, ASCO, Annual Meeting. Arcus is pursuing a broad development program in both the immuno-oncology-naive and post-IO settings with differentiated combinations to maximize the opportunity for casdatifan in ccRCC. These studies include: Arcus's planned Phase 3 study, PEAK-1, which will evaluate casdatifan plus cabozantinib versus cabozantinib monotherapy as a first- or second-line treatment in patients with metastatic ccRCC who have previously received anti-PD-1/PD-L1 therapy. The primary endpoint will be PFS with a key secondary endpoint of overall survival. eVOLVE-RCC02, a Phase 1b/3 study sponsored by AstraZeneca, which will evaluate casdatifan plus volrustomig, an investigational anti-PD-1/CTLA-4 bispecific antibody, as first-line treatment for participants with ccRCC. ARC-20, which includes three cohorts evaluating casdatifan in earlier-line settings, including casdatifan plus zimberelimab in first-line ccRCC, casdatifan monotherapy in favorable risk ccRCC, and casdatifan monotherapy in immunotherapy-experienced, TKI-naive settings. Confident Investing Starts Here: